AGIXAtheroGenics, Inc (stock symbol)
References in periodicals archive ?
The question now seems to be who, if anyone, will pick up the pieces of the late-phase candidates AGIX had been developing.
Mike Viracola, managing director and co-head of equities, Adams Harkness New PriceWatch Alerts for AMTD, L, UTSI, HON, and AGIX.
If you purchased or otherwise acquired AGIX securities after the Company issued its September 27, 2004 interim study results through and including December 31, 2004, and have been damaged thereby, you may request that the Court appoint you as lead plaintiff no later than March 7, 2005.
Turning now to AGIX, I notice that 6,403 of the firm's January 20 call (AUB AD) crossed the tape this morning.
Yesterday afternoon, we learned that AstraZeneca has entered into a licensing deal with AGIX for the global development and commercialization of its anti-inflammatory cardiovascular product candidate, AGI-1067.
This sentiment allows room for downgrades, but it's interesting to note that five brokerages, almost half of those that express a preference, have AGIX at a cautious "hold" or worse.
5 million AGIX shares are currently sold short, and the number increased by more than 10 percent during November.
In the options pits, today's Schaeffer's put/call open interest ratio (SOIR) for AGIX is 0.
AGIX sports a Schaeffer's Equity Scorecard rating of 6.
Company: AtheroGenics Ticker Symbol: AGIX Media Contact: Donna Glasky Investor Relations Contact: Donna Glasky Phone: 678-336-2517 E-mail: dglasky@atherogenics.
We recommend long-term investors buy the shares, but we downgrade AGIX to a Hold at this time.